1. 1) Pateisky K. Treatment of myasthenia gravis pseudoparalytica; clinical testing and therapy with BC substances (BC40, BC47, BC48 and BC 51). Wien. Z. Nervenheilkd. Grenzgeb., 17, 53–84 (1959).
2. 2) Matsuura R, Hamano S, Nakashima E, Suzuki K, Kikuchi K, Tanaka M, Minamitani M, Ida H. Prolonged remission by immunoglobulin therapy without steroids in a pediatric patient with myasthenia gravis. Syounika Rinsyo, 66, 317–321 (2013).
3. 3) Ishikawa S, Tsukahara S, Sato Y. Local administration of 1% Ubretid in the handling of glaucoma, myasthenia gravis and esotropia. Ophthalmologica, 159, 339–362 (1969).
4. 4) Inada T, Ebisuta K, Harada T. Use of “Ubretid” in the field of urology. Hinyokika Kiyo, 13, 429–432 (1967).
5. 5) Niijima T, Asano M. Clinical appraisal of Ubretid: a new cholinesterase inhibitor. Hinyokika Kiyo, 13, 423–428 (1967).